Tags

Type your tag names separated by a space and hit enter

New data on chronic venous disease: a new place for Cyclo 3® Fort.
Int Angiol. 2018 Feb; 37(1):85-92.IA

Abstract

With our increasing knowledge of the epidemiology, pathophysiology, investigation and clinical aspects of chronic venous disease (CVD) and new data on the various therapies available, an update of the recommendations on CVD and its management appears to be necessary. The symposium New Data on Chronic Venous Disease: A New Place for Cyclo 3® Fort, held during the annual meeting of the European Venous Forum on June 30th, 2017 in Porto, Portugal, reported the recent developments on the Ruscus, hesperidin methyl chalcone (HMC), and vitamin C combination (Cyclo 3® Fort), including the results of a series of in-vivo pharmacological experiments and a recent meta-analysis. Additionally, the symposium provided first-hand information on the process, rules, main findings, and expected contents of the prospective 2018 CVD guidelines. Analysis of the evidence showed that the effect of the Ruscus, HMC, and vitamin C combination on pain, heaviness, feeling of swelling, tingling, ankle circumference and global symptoms score reached Grade A. Therefore, the new guidelines should specify that the Ruscus, HMC, and vitamin C combination merits a Grade 1A recommendation.

Authors+Show Affiliations

Department of Vascular Surgery, University Hospital of Patras, Patras, Greece - kakkos@upatras.gr.Laboratory of Clinical and Experimental Research on Vascular Biology-BioVasc-State University of Rio de Janeiro, Rio de Janeiro, Brazil.Department of Vascular Surgery and Angiology, Collegium Medicum University of Nicolai Copernicus, Bydgoszcz, Poland.Department of Surgery, University of Nicosia Medical School, Nicosia, Cyprus.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

29063748

Citation

Kakkos, Stavros K., et al. "New Data On Chronic Venous Disease: a New Place for Cyclo 3® Fort." International Angiology : a Journal of the International Union of Angiology, vol. 37, no. 1, 2018, pp. 85-92.
Kakkos SK, Bouskela E, Jawien A, et al. New data on chronic venous disease: a new place for Cyclo 3® Fort. Int Angiol. 2018;37(1):85-92.
Kakkos, S. K., Bouskela, E., Jawien, A., & Nicolaides, A. N. (2018). New data on chronic venous disease: a new place for Cyclo 3® Fort. International Angiology : a Journal of the International Union of Angiology, 37(1), 85-92. https://doi.org/10.23736/S0392-9590.17.03935-9
Kakkos SK, et al. New Data On Chronic Venous Disease: a New Place for Cyclo 3® Fort. Int Angiol. 2018;37(1):85-92. PubMed PMID: 29063748.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - New data on chronic venous disease: a new place for Cyclo 3® Fort. AU - Kakkos,Stavros K, AU - Bouskela,Eliete, AU - Jawien,Arkadiusz, AU - Nicolaides,Andrew N, Y1 - 2017/10/23/ PY - 2017/10/25/pubmed PY - 2018/8/17/medline PY - 2017/10/25/entrez SP - 85 EP - 92 JF - International angiology : a journal of the International Union of Angiology JO - Int Angiol VL - 37 IS - 1 N2 - With our increasing knowledge of the epidemiology, pathophysiology, investigation and clinical aspects of chronic venous disease (CVD) and new data on the various therapies available, an update of the recommendations on CVD and its management appears to be necessary. The symposium New Data on Chronic Venous Disease: A New Place for Cyclo 3® Fort, held during the annual meeting of the European Venous Forum on June 30th, 2017 in Porto, Portugal, reported the recent developments on the Ruscus, hesperidin methyl chalcone (HMC), and vitamin C combination (Cyclo 3® Fort), including the results of a series of in-vivo pharmacological experiments and a recent meta-analysis. Additionally, the symposium provided first-hand information on the process, rules, main findings, and expected contents of the prospective 2018 CVD guidelines. Analysis of the evidence showed that the effect of the Ruscus, HMC, and vitamin C combination on pain, heaviness, feeling of swelling, tingling, ankle circumference and global symptoms score reached Grade A. Therefore, the new guidelines should specify that the Ruscus, HMC, and vitamin C combination merits a Grade 1A recommendation. SN - 1827-1839 UR - https://www.unboundmedicine.com/medline/citation/29063748/New_data_on_chronic_venous_disease:_a_new_place_for_Cyclo_3®_Fort_ L2 - https://www.minervamedica.it/index2.t?show=R34Y2018N01A0085 DB - PRIME DP - Unbound Medicine ER -